Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
1.980
-0.060 (-2.94%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Cibus Revenue
In the year 2024, Cibus had annual revenue of $4.26M with 134.56% growth. Cibus had revenue of $1.21M in the quarter ending December 31, 2024, with 9.88% growth.
Revenue (ttm)
$4.26M
Revenue Growth
+134.56%
P/S Ratio
10.79
Revenue / Employee
$23,290
Employees
183
Market Cap
68.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.26M | 2.45M | 134.56% |
Dec 31, 2023 | 1.82M | 1.66M | 1,057.32% |
Dec 31, 2022 | 157.00K | -25.83M | -99.40% |
Dec 31, 2021 | 25.99M | 2.14M | 8.96% |
Dec 31, 2020 | 23.85M | 16.56M | 226.91% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CBUS News
- 10 days ago - Cibus, Inc. (CBUS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Cibus Reports Fourth Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 13 days ago - Cibus Welcomes the European Union's Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward - GlobeNewsWire
- 19 days ago - Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call - GlobeNewsWire
- 26 days ago - Cibus' Achieves Another Milestone for a Durable White Mold (Sclerotinia) Resistance Trait in Canola - GlobeNewsWire
- 4 weeks ago - Cibus Announces Leadership Change and CEO Succession Plan - GlobeNewsWire
- 6 weeks ago - Cibus Announces Important Update to Rice Gene Editing Conversion Rates - GlobeNewsWire
- 2 months ago - Cibus to Participate in the Sidoti Micro Cap Conference - GlobeNewsWire